Table 1.
Baseline Characteristics of the eligible studies
| Author | Year | Study design | No. of patients |
Country | Ethnicity | Cut-off value |
Method | Median follow up |
pCR definition |
Outcome | Analysis | Treatment | Time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Loi et al. | 2014 | prospective-retrospective | 209 | multicenter | Mix | 10% INC | H&E | 62 months | - | DDFS | univariate | D, FEC, H | Adjuvant setting |
| Denkert et al. |
2015 | prospective | 266 | USA | Caucasian | 10% INC | H&E | NA | ypT0is ypN0 | pCR | multivariate | PMCb, H | Neoadjuvant setting |
| Kotoula et al. |
2016 | retrospective | 333 | Greece | Caucasian | >35% | H&E | NA | - | DFS | univariate | A/T, H | Adjuvant setting |
| Liu et al. | 2015 | retrospective | 116 | China | Asian | ≥30% | H&E | 33 months | ypT0is ypN0 | pCR, EFS | multivariate | T/Cb, H | Neoadjuvant setting |
| Perez et al. | 2016 | prospective-retrospective | 456 | America | Caucasian | 10% INC | H&E | 4.4 years | - | RFS | multivariate | DC, P, H | Adjuvant setting |
| Lee et al. | 2015 | retrospective | 447 | Korea | Asian | 10% INC | H&E | 49 months | - | DFS | multivariate | AC,P/D, H | Adjuvant setting |
| Salgado et al. |
2015 | retrospective | 250 | Australia | Caucasian | >5%, 1% INC |
H&E | 3.77 years | ypT0is ypN0 | pCR EFS |
multivariate | P, H, L | Neoadjuvant setting |
| Luen et al. | 2017 | retrospective | 678 | multicenter | Mix | 10% INC | H&E | 50 months | - | PFS | multivariate | H, D,Pe/Pl | Adjuvant setting |
| Heppner et al. |
2016 | retrospective | 340 | multicenter | Mix | 10% INC | H&E | NA | ypT0is ypN0 | pCR | multivariate | EC, D/Cb, H | Neoadjuvant setting |
| Liu et al. | 2016 | retrospective | 101 | China | Asian | NA | IHC | NA | ypT0is ypN0 | pCR | multivariate | TC, H | Neoadjuvant setting |
| Dieci et al. | 2016 | prospective | 32 | USA | Caucasian | 1% INC | H&E | NA | ypT0is ypN0 | pCR | NA | P, FEC, H | Neoadjuvant setting |
Abbreviations: H&E, Hematoxylin-eosin staining; 10% INC, 10% increment; LPBC, lymphocyte-predominant breast cancer: ≧60%; pCR, pathological complete response; DFS, disease-free survival; DDFS, distant disease-free survival; EFS, event-free survival; RFS, recurrence-free survival; PFS, progression-free survival; OS, overall survival; NA, not available; AC, anthracycline-cyclophosphamide; P, paclitaxel; DC, doxorubicin-cyclophosphamide; D, docetaxel; FEC, fluorouracil/epirubicin/cyclophosphamide; T, taxanes; Cb, carboplatin; Pe, pertuzumab; Pl, placebo; L, lapatinib; PMCb, paclitaxel/doxorubicin/capecitabine; TC, taxanes-cyclophosphamide; H, trastuzumab.